| AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Transl Res 2011;3(4):362-373
Review Article
Urothelial carcinomas: a focus on human epidermal receptors
signaling
Petros D. Grivas, Mark Day, Maha Hussain
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109,
USA; Department of Urology, University of Michigan, Ann Arbor, M 48109, USA
Received June 21, 2011; accepted July 15, 2011; Epub July 25, 2011; Published August 15, 2011
Abstract: Bladder cancer is a common malignancy and a frequent cause of cancer-related death worldwide. The
benefit from current chemotherapy has reached a relative plateau, thus identification of molecular targets for
better therapy is a high priority. Human epidermal receptors constitute a family of receptor tyrosine kinases, which
appear to be implicated in cellular transformation and can be over-expressed in a variety of solid tumors. There is
preclinical and clinical data suggesting the role of EGFR and HER2 in urothelial carcinoma, thus prompting
clinical investigation of anti-HER targeted therapies attempting to inhibit HER-induced tumor-promoting signaling.
There is significant and dynamic cross-talk between HER and other signaling pathways and the identification of
the structure and function of such cellular networks in the setting of urothelial cancer is a complex and difficult
task. The development of prognostic and predictive biomarkers is needed in order to improve the personalized
management of patients with urothelial cancer. (AJTR1106004).
Keywords: Bladder cancer, urothelial carcinoma, human epidermal receptors, EGFR, HER2, trastuzumab
Full Text PDF
Address all correspondence to:
Maha Hussain, MD
Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan
Ann Arbor, MI 48109, USA.
Tel: 734-936-8906
Fax: 734-615-2719
E-mail: mahahuss@med.umich.edu
Review Article
Urothelial carcinomas: a focus on human epidermal receptors
signaling
Petros D. Grivas, Mark Day, Maha Hussain
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109,
USA; Department of Urology, University of Michigan, Ann Arbor, M 48109, USA
Received June 21, 2011; accepted July 15, 2011; Epub July 25, 2011; Published August 15, 2011
Abstract: Bladder cancer is a common malignancy and a frequent cause of cancer-related death worldwide. The
benefit from current chemotherapy has reached a relative plateau, thus identification of molecular targets for
better therapy is a high priority. Human epidermal receptors constitute a family of receptor tyrosine kinases, which
appear to be implicated in cellular transformation and can be over-expressed in a variety of solid tumors. There is
preclinical and clinical data suggesting the role of EGFR and HER2 in urothelial carcinoma, thus prompting
clinical investigation of anti-HER targeted therapies attempting to inhibit HER-induced tumor-promoting signaling.
There is significant and dynamic cross-talk between HER and other signaling pathways and the identification of
the structure and function of such cellular networks in the setting of urothelial cancer is a complex and difficult
task. The development of prognostic and predictive biomarkers is needed in order to improve the personalized
management of patients with urothelial cancer. (AJTR1106004).
Keywords: Bladder cancer, urothelial carcinoma, human epidermal receptors, EGFR, HER2, trastuzumab
Full Text PDF
Address all correspondence to:
Maha Hussain, MD
Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan
Ann Arbor, MI 48109, USA.
Tel: 734-936-8906
Fax: 734-615-2719
E-mail: mahahuss@med.umich.edu
 | |  | |  | |  | |  | |  | |  |